Provided by Tiger Fintech (Singapore) Pte. Ltd.

Voyager Therapeutics

3.20
-0.2100-6.16%
Volume:168.29K
Turnover:542.18K
Market Cap:176.66M
PE:-2.83
High:3.30
Open:3.26
Low:3.17
Close:3.41
Loading ...

Voyager Therapeutics Shares up 6.9% Premarket After Wedbush Assumes Coverage With Outperform Rating

THOMSON REUTERS
·
29 Nov 2024

Wedbush Upgrades Voyager Therapeutics to Outperform From Neutral, Raises Price Target to $11 From $7

MT Newswires Live
·
29 Nov 2024

Wedbush upgrades Voyager to Outperform on pipeline progress

TIPRANKS
·
29 Nov 2024

Voyager Therapeutics assumed with Outperform from Neutral at Wedbush

TIPRANKS
·
29 Nov 2024

Voyager Therapeutics Inc : Wedbush Assumes Coverage With Outperform VS Neutral Rating; Target Price $11 VS $7

THOMSON REUTERS
·
29 Nov 2024

Voyager Therapeutics Selects Development Candidate for Tau Silencing Program in Alzheimer's Disease

MT Newswires Live
·
20 Nov 2024

Voyager selects gene therapy development candidate for Alzheimer’s disease

seekingalpha
·
20 Nov 2024

BRIEF-Voyager Selects Tau Silencing Gene Therapy Development Candidate for Alzheimer’s Disease

Reuters
·
20 Nov 2024

Voyager Selects Tau Silencing Gene Therapy Development Candidate for Alzheimer’s Disease

THOMSON REUTERS
·
20 Nov 2024

Voyager Therapeutics : Candidate Vy1706 Demonstrates Significant Reductions of Tau at Low Doses in Nhp Study; Ind & Cta Filings Anticipated in 2026

THOMSON REUTERS
·
20 Nov 2024

Voyager Therapeutics Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
15 Nov 2024

Analysts Are Bullish on Top Healthcare Stocks: Voyager Therapeutics (VYGR), BioNTech SE (BNTX)

TIPRANKS
·
14 Nov 2024

Declining Stock and Decent Financials: Is The Market Wrong About Voyager Therapeutics, Inc. (NASDAQ:VYGR)?

Simply Wall St.
·
14 Nov 2024

Voyager Therapeutics Price Target Maintained With a $30.00/Share by HC Wainwright & Co.

Dow Jones
·
14 Nov 2024

Voyager Therapeutics: Promising Alzheimer’s Program and Strong Financial Position Support Buy Rating

TIPRANKS
·
14 Nov 2024

Voyager Therapeutics’ Innovative CNS Pipeline and Promising Alzheimer’s Developments Justify Buy Rating

TIPRANKS
·
14 Nov 2024

Q3 2024 Voyager Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents
·
13 Nov 2024

Voyager Therapeutics Inc : Leerink Partners Cuts Target Price to $14 From $15

THOMSON REUTERS
·
13 Nov 2024

Voyager Therapeutics Inc (VYGR) Q3 2024 Earnings Call Highlights: Strong Cash Position and ...

GuruFocus.com
·
13 Nov 2024

Voyager Therapeutics: Solid Financial Foundation and Strategic Progress Justify Buy Rating

TIPRANKS
·
13 Nov 2024